Most Recent
The judge overseeing a fraudulent concealment trial over Cargill's $420 million purchase of the Joe White malt business has reaffirmed an earlier ruling allowing an in-house counsel at Glencore to access documents related to the possible sale of Cargill's malting business.
The former managing director of Murray Goulburn will be hit with a $200,000 penalty for being knowingly concerned in false representations made by the dairy producer to farmers about the farmgate milk prices it would pay during the 2015-16 milk season.
ANZ treasurer Rick Moscati was at the centre of a flurry of phone calls and meetings with underwriters and other bank executives on the day the underwriters agreed to pick up a $791 million shortfall in a $2.5 billion capital raising, an agreement which has led to groundbreaking cases by two regulators, according to a new court document.
AMP's advice executive Jack Regan, the witness who aired the firm's fees-for-no-service dirty laundry at the Royal Commission, has retired, a day before five law firms compete to lead a class action over the scandal.
Two NAB wealth management units have admitted to engaging in misleading and deceptive conduct by deducting $34.4 million in fees for services that were never provided.
Pharmaceutical giant Wyeth has accused Merck Sharp & Dohme of a "baseless" patent invalidity case, saying on the second day of trial over the world's best selling vaccine that the development of its patented Prevnar 13 pneumococcal shot was anything but obvious, as its rival contends.
A chain of cosmetic surgery clinics has lost its fight to have a class action of over 200 patients allegedly injured by botched breast augmentation surgery discontinued as a representative proceeding.
The Commonwealth Bank of Australia is open to a proposal to consolidate two shareholder class actions filed over alleged breaches of anti-money laundering and counter-terrorism laws, but will address any "devil in the details", a lawyer for the bank told a court Tuesday.
Accounting giant Ernst & Young, which is accused in a class action of misleading and deceptive conduct in signing off on the 2015 and 2016 financial reports of sandalwood producer Quintis, has named the company's previous auditor as partly to blame in any finding of liability.
A showdown between global pharmaceutical giants over the world's best selling vaccine began Monday in Federal Court, with Merck Sharp & Dohme claiming three patents for Prevnar 13 sold by Pfizer's Wyeth are invalid and that its own vaccine offers greater protection against pneumococcal bacteria.